<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00069160</url>
  </required_header>
  <id_info>
    <org_study_id>030284</org_study_id>
    <secondary_id>03-C-0284</secondary_id>
    <secondary_id>030284</secondary_id>
    <nct_id>NCT00069160</nct_id>
    <nct_alias>NCT00072202</nct_alias>
  </id_info>
  <brief_title>Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer</brief_title>
  <official_title>A Clinical Trial of the P-Glycoprotein Antagonist, Tariquidar (XR9576), in Combination With Docetaxel in Patients With Lung, Ovarian, Renal and Cervical Cancer: Analysis of the Interaction Between Tariquidar and Docetaxel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is three-fold: 1) to examine the ability of the experimental drug
      tariquidar to improve chemotherapy results by blocking a protein (P-glycoprotein) on some
      cancer cells that acts to pump out cancer drugs; 2) examine how tariquidar interacts with the
      cancer drug docetaxel; and 3) evaluate the effectiveness of combination treatment with
      tariquidar and docetaxel in treating patients with lung, ovarian, or cervical cancer.

      Patients 18 years of age and older with recurrent or metastatic (spreading) lung, cervical,
      or ovarian cancer who cannot benefit from any standard treatment may be eligible for this
      study. Candidates will be screened with a medical history and physical examination; review of
      pathology slides; blood and urine tests; imaging tests, including computed tomography (CT) or
      magnetic resonance imaging (MRI) scans; chest x-ray, electrocardiogram (EKG); and possibly
      echocardiogram.

      Participants will undergo the following tests and procedures:

      Blood draw. Blood is drawn before treatment begins to establish baseline levels for future
      blood tests. Blood counts are done twice weekly after chemotherapy begins.

      Central venous catheter placement. A plastic tube is put into a major vein in the chest. It
      is used to give the study drugs or other medications, including antibiotics and blood
      transfusions, if needed, and to withdraw blood samples. The line is usually placed under
      local anesthesia in the radiology department or the operating room. It can stay in the body
      for months or be removed after each treatment is completed.

      Chemotherapy. Treatment cycles are 21 days. Both drugs are given on day 1 of each cycle.
      First, tariquidar is given as a 30-minute infusion. One hour after the tariquidar infusion,
      docetaxel is infused over 1 hour. (For the first cycle only, docetaxel is given in divided
      doses one week apart and tariquidar is administered on either day 1 or day 8. The order of
      tariquidar administration is randomized to generate optimal pharmacokinetic data. Patients
      will be hospitalized for several days during this cycle to gather research data). The
      tariquidar dose remains the same throughout the study. Docetaxel may be increased or
      decreased from cycle to cycle, based on side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intrinsic and acquired drug resistance remain major obstacles in the treatment of cancer.
      Accumulating evidence indicates that in some malignancies P-glycoprotein (Pgp) can confer
      resistance, and that its reversal can improve therapeutic outcome. Clinical trials
      investigating Pgp antagonists have been hampered by the occurrence of unpredictable
      pharmacokinetic interactions, which have required dose reductions of the chemotherapeutic
      agents to avert excessive toxicity. Tariquidar (XR9576) is a new Pgp antagonist that is more
      potent and has prolonged activity. Phase I trials with paclitaxel, vinorelbine, and docetaxel
      have demonstrated that tariquidar (XR9576) has minimal pharmacokinetic interactions while
      surrogate studies have confirmed in vivo inhibition of Pgp-mediated drug transport.This study
      seeks to determine the pharmacokinetic interaction, if any between docetaxel and tariquidar
      and to evaluate the potential for activity in lung, ovarian, primary peritoneal, fallopian
      tube and cervical cancers. Renal cell cancer has been added in a 3/1/06 amendment. The
      secondary goal is to evaluate the impact of tariquidar on uptake of (99m)Tc-sestamibi in
      recurrent or metastatic tumors of patients with lung, ovarian, renal or cervical cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean of Maximum Concentration of the Drug (Cmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>In the first cycle patients were to receive docetaxel on days 1 and 8 and to be randomized to receive tariquidar on either day 1 or 8. Thus pharmacokinetic data with and without tariquidar can be compared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Participants With Adverse Events.</measure>
    <time_frame>4 yrs 8-11 months</time_frame>
    <description>Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Area Under Curve (AUC0)-24</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Response Rate</measure>
    <time_frame>4 years, 8-11 months</time_frame>
    <description>Response is determined by RECIST criteria defined as changes in only the largest diameter (unidimensional measurement) of the tumor lesion. Lesions are either measurable or non-measurable. Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as &gt;/- 20 mm with conventional techniques (CT, MRI, xray) or as &gt;/- 10 mm with a spiral CT scan. Non-measurable lesions are defined as all other lesions (or sites of disease) including small lesions (longest diameter &lt;20 mm with conventional techniques or &lt;10 mm using spiral CT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Increase in Sestamibi Area Under Curve (AUC) in Liver After Tariquidar</measure>
    <time_frame>3 - 24 hours</time_frame>
    <description>A significant change in the area under the curve(AUC) in liver tissue (normal tissue as a surrogate) is defined as P&lt;0.001. A secondary objective of this study was to establish whether tariquidar (150 mg) modulates Pgp in liver. Sestamibi is a Pgp substrate that may be a surrogate for measuring drug efflux from tumors. A baseline Tc-sestamibi scan was obtained before the administration of tariquidar. A minimum of 48 hours later, on or about day 22 a single dose of tariquidar was administered, followed by a second Tc-sestamibi scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Increase in Sestamibi Area Under Curve (AUC) in Tumor Tissue</measure>
    <time_frame>3-24 hours</time_frame>
    <description>99mTc-sestamibi is a radionuclide imaging agent used to study cardiac function that has also been shown to be a substrate for P-glycoprotein- mediated drug efflux. Because of the high expression of Pgp in liver tissue, sestamibi uptake in liver tissue is often monitored as a marker of Pgp inhibition. A significant change in the area under the curve(AUC) in liver tissue (normal tissue as a surrogate) is defined as P&lt;0.001.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Lung Neoplasms</condition>
  <condition>Ovarian Neoplasms</condition>
  <condition>Cervix Neoplasms</condition>
  <condition>Renal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Pts who received docetaxel on day 1, 8, &amp; tariquidar day 8,22</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pts who received docetaxel on days 1, 8, &amp; tariquidar day 1,22</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8 and tariquidar intravenous (IV) over 30 minutes on days 1 and 22.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8.</description>
    <arm_group_label>Pts who received docetaxel on day 1, 8, &amp; tariquidar day 8,22</arm_group_label>
    <arm_group_label>Pts who received docetaxel on days 1, 8, &amp; tariquidar day 1,22</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tariquidar</intervention_name>
    <description>Patients receive tariquidar intravenous (IV) over 30 minutes on days 8 and 22.</description>
    <arm_group_label>Pts who received docetaxel on day 1, 8, &amp; tariquidar day 8,22</arm_group_label>
    <arm_group_label>Pts who received docetaxel on days 1, 8, &amp; tariquidar day 1,22</arm_group_label>
    <other_name>XR9576</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>99mTc-sestamibi imaging</intervention_name>
    <description>Bolus injection of 29 mCi of 99mTc-sestamibi intravenously for each imaging study.</description>
    <arm_group_label>Pts who received docetaxel on day 1, 8, &amp; tariquidar day 8,22</arm_group_label>
    <arm_group_label>Pts who received docetaxel on days 1, 8, &amp; tariquidar day 1,22</arm_group_label>
    <other_name>Cardiolite</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must fulfill all of the following criteria to be eligible for study
             admission:

          -  Age greater than or equal to 18 years.

          -  Histologic or cytologic confirmation of lung, cervical, or ovarian cancer, following
             at least one standard treatment regimen, and for which there is no known standard
             therapy capable of extending life expectancy. Female patients with primary papillary
             carcinoma of the peritoneum and fallopian tube cancers will be included in the latter
             group, as the disease entities are closely associated with epithelial ovarian
             carcinoma, can be difficult to distinguish, have a similar epithelial origin, and are
             treated in an identical manner.

          -  Histologic or cytologic confirmation of renal cell carcinoma (clear cell, type 1 and
             type II papillary chromophobe, collecting duct and medullary). Patients should have
             received either sunitinib or sorafenib, unless deemed ineligible for treatment with
             either agent. In addition,patient should either: (a) have received IL-2; (b) have been
             evaluated for therapy with Interleukin-2 (IL- 2) and deemed to be ineligible; or (c)
             have been evaluated for therapy with IL2 and refused treatment.

          -  Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2

          -  Life expectancy of 3 months or greater.

          -  Suitable candidate for receiving planned therapy as evidenced by screening laboratory
             assessments hematologic, renal hepatic, and metabolic functions, platelet count
             greater than or equal to 90,000/mL, absolute granulocyte count(AGC) greater than or
             equal to 1,500/mL, serum creatinine greater than or equal to 1,500/mL, serum creatine
             less than or equal to 1.5 mg/dl )or if greater than 1.5 a measured 24 hour creatinine
             clearance greater than or equal to 50 mL/min) and serum glutamic oxaloacetic
             transaminase (SGOT) less than or equal to 2.5 x normal limit (NL) and bilirubin less
             than or equal to 1.5 x NL (in patients with clinical evidence of Gilbert's
             disease,less than or equal to 3 x NL).

          -  Patients must be greater than or equal to 4 weeks prior radiation or chemotherapy,
             greater than 2 weeks from hormonal therapy; greater than 4 weeks from prior
             experimental therapy; greater than 6 weeks from mitomycin C; and greater than 8 weeks
             from prior UCN01 treatment.

          -  No serious intercurrent medical illness.

          -  Measurable disease by radiographic means or physical examination. For ovarian cancer,
             assessable disease by cancer antigen 125 (CA125) measurement is allowed.

          -  Willingness to sign a written consent form, and to comply with the protocol.

        Exclusion Criteria:

          -  The following patient populations are not eligible for this study.

          -  Pregnant or nursing women are not eligible; women of childbearing age must agree to
             use an effective method of contraception. Pregnant women are not eligible because of
             teratogenic effects of chemotherapy.

          -  The presence of a second malignancy that has not received primary treatment or would
             complicate the primary objective of this study.

          -  Patients who are poor medical risk because of active, uncontrolled infection or other
             nonmalignant systemic disease.

          -  Human immunodeficiency virus (HIV) seropositive patients. Patients infected with the
             HIV virus will be excluded from this trial because the effect of the combination of
             tariquidar and docetaxel on HIV replication and/or the immune system is unknown and
             potentially harmful.

          -  Patients receiving agents which have major interactions with the cytochrome P450 3A4
             (CYP3A4)drug metabolizing system and which cannot be discontinued may not be included
             in the trial.

          -  Untreated brain metastases (or local treatment of brain metastases within the last 6
             months) due to the poor prognosis of these patients and difficulty ascertaining the
             cause of neurologic toxicities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan E Bates, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI, NIH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/</url>
    <description>Medline Plus</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp</url>
    <description>Drug Information</description>
  </link>
  <link>
    <url>http://www.clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>U.S. FDA Resources</description>
  </link>
  <reference>
    <citation>Ling V, Thompson LH. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol. 1974 Feb;83(1):103-16.</citation>
    <PMID>4855907</PMID>
  </reference>
  <reference>
    <citation>Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesman MM. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet. 1985 Mar;11(2):117-26.</citation>
    <PMID>3856953</PMID>
  </reference>
  <reference>
    <citation>Beck WT, Cirtain MC, Lefko JL. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts. Mol Pharmacol. 1983 Nov;24(3):485-92.</citation>
    <PMID>6579344</PMID>
  </reference>
  <results_reference>
    <citation>Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM, Steinberg SM, Fojo T, Bates SE. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res. 2011 Feb 1;17(3):569-80. doi: 10.1158/1078-0432.CCR-10-1725. Epub 2010 Nov 16.</citation>
    <PMID>21081657</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2003</study_first_submitted>
  <study_first_submitted_qc>September 15, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2003</study_first_posted>
  <results_first_submitted>June 30, 2011</results_first_submitted>
  <results_first_submitted_qc>September 12, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 12, 2012</results_first_posted>
  <last_update_submitted>September 12, 2012</last_update_submitted>
  <last_update_submitted_qc>September 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2012</last_update_posted>
  <responsible_party>
    <name_title>Susan E. Bates</name_title>
    <organization>National Cancer Institute (NCI), National Institutes of Health (NIH)</organization>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Multidrug Resistance Reversal</keyword>
  <keyword>Molecular Target</keyword>
  <keyword>P-Glycoprotein Inhibition</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Cervical Cancer</keyword>
  <keyword>Renal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Technetium Tc 99m Sestamibi</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pts Who Received Docetaxel on Day 1, 8, &amp; Tariquidar Day 8,22</title>
          <description>Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg tariquidar dose.</description>
        </group>
        <group group_id="P2">
          <title>Pts Who Received Docetaxel on Days 1, 8, &amp; Tariquidar Day 1,22</title>
          <description>Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8 and tariquidar intravenous (IV) over 30 minutes on days 1 and 22.From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg tariquidar dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pts Who Received Docetaxel on Day 1, 8, &amp; Tariquidar Day 8,22</title>
          <description>Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg tariquidar dose.</description>
        </group>
        <group group_id="B2">
          <title>Pts Who Received Docetaxel on Days 1, 8, &amp; Tariquidar Day 1,22</title>
          <description>Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8 and tariquidar intravenous (IV) over 30 minutes on days 1 and 22.From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg tariquidar dose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.76" spread="9.54"/>
                    <measurement group_id="B2" value="55.77" spread="9.57"/>
                    <measurement group_id="B3" value="53.37" spread="9.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Maximum Concentration of the Drug (Cmax)</title>
        <description>In the first cycle patients were to receive docetaxel on days 1 and 8 and to be randomized to receive tariquidar on either day 1 or 8. Thus pharmacokinetic data with and without tariquidar can be compared.</description>
        <time_frame>24 hours</time_frame>
        <population>Docetaxel alone (C1D1 = 21 patients; C1D8 = 18 patients) Docetaxel with Tariquidar (C1D1 = 21 patients; C1D8 = 16 patients) Data were evaluable in 39 patients. Paired data from 31 participants were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel Alone</title>
            <description>40 mg/m^2 docetaxel over 1 hour on days 1 and 8.</description>
          </group>
          <group group_id="O2">
            <title>With Tariquidar</title>
            <description>40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on either day 1 or 8 and then again on day 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose of tariquidar.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Maximum Concentration of the Drug (Cmax)</title>
          <description>In the first cycle patients were to receive docetaxel on days 1 and 8 and to be randomized to receive tariquidar on either day 1 or 8. Thus pharmacokinetic data with and without tariquidar can be compared.</description>
          <population>Docetaxel alone (C1D1 = 21 patients; C1D8 = 18 patients) Docetaxel with Tariquidar (C1D1 = 21 patients; C1D8 = 16 patients) Data were evaluable in 39 patients. Paired data from 31 participants were evaluable.</population>
          <units>Cmax (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C1D1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1315" lower_limit="1081" upper_limit="1598"/>
                    <measurement group_id="O2" value="1093" lower_limit="791.2" upper_limit="1510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1D8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1060" lower_limit="773.5" upper_limit="1452"/>
                    <measurement group_id="O2" value="1026" lower_limit="807.3" upper_limit="1303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Both Groups (C1D1 + C1D8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1190" lower_limit="999.9" upper_limit="1416"/>
                    <measurement group_id="O2" value="1063" lower_limit="869.2" upper_limit="1301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants With Adverse Events.</title>
        <description>Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
        <time_frame>4 yrs 8-11 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients on Docetaxel on Days 1, 8 &amp; Tariquidar on Day 8, 22</title>
            <description>Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.</description>
          </group>
          <group group_id="O2">
            <title>Patients on Docetaxel on Days 1, 8 &amp; Tariquidar on Days 1, 22</title>
            <description>Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Adverse Events.</title>
          <description>Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Area Under Curve (AUC0)-24</title>
        <time_frame>24 hours</time_frame>
        <population>Docetaxel alone (C1D1 = 21 patients; C1D8 = 18 patients) Docetaxel with Tariquidar (C1D1 = 21 patients; C1D8 = 16 patients) Pharmacokinetic data were evaluable in 39 patients. Paired data from 31 participants were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel Alone</title>
            <description>40 mg/m^2 docetaxel over 1 hour on days 1 and 8.</description>
          </group>
          <group group_id="O2">
            <title>With Tariquidar</title>
            <description>40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on either day 1 or 8 and then again on day 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose of tariquidar.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Area Under Curve (AUC0)-24</title>
          <population>Docetaxel alone (C1D1 = 21 patients; C1D8 = 18 patients) Docetaxel with Tariquidar (C1D1 = 21 patients; C1D8 = 16 patients) Pharmacokinetic data were evaluable in 39 patients. Paired data from 31 participants were evaluable.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C1D1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1367" lower_limit="1126" upper_limit="1658"/>
                    <measurement group_id="O2" value="1409" lower_limit="1172" upper_limit="1694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1D8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1308" lower_limit="989.8" upper_limit="1730"/>
                    <measurement group_id="O2" value="1327" lower_limit="1084" upper_limit="1623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Both Groups (C1D1 + C1D8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1339" lower_limit="1144" upper_limit="1568"/>
                    <measurement group_id="O2" value="1373" lower_limit="1206" upper_limit="1563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Response Rate</title>
        <description>Response is determined by RECIST criteria defined as changes in only the largest diameter (unidimensional measurement) of the tumor lesion. Lesions are either measurable or non-measurable. Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as &gt;/- 20 mm with conventional techniques (CT, MRI, xray) or as &gt;/- 10 mm with a spiral CT scan. Non-measurable lesions are defined as all other lesions (or sites of disease) including small lesions (longest diameter &lt;20 mm with conventional techniques or &lt;10 mm using spiral CT.</description>
        <time_frame>4 years, 8-11 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients Who Received Docetaxel and Tariquidar</title>
            <description>Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response Rate</title>
          <description>Response is determined by RECIST criteria defined as changes in only the largest diameter (unidimensional measurement) of the tumor lesion. Lesions are either measurable or non-measurable. Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as &gt;/- 20 mm with conventional techniques (CT, MRI, xray) or as &gt;/- 10 mm with a spiral CT scan. Non-measurable lesions are defined as all other lesions (or sites of disease) including small lesions (longest diameter &lt;20 mm with conventional techniques or &lt;10 mm using spiral CT.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Increase in Sestamibi Area Under Curve (AUC) in Liver After Tariquidar</title>
        <description>A significant change in the area under the curve(AUC) in liver tissue (normal tissue as a surrogate) is defined as P&lt;0.001. A secondary objective of this study was to establish whether tariquidar (150 mg) modulates Pgp in liver. Sestamibi is a Pgp substrate that may be a surrogate for measuring drug efflux from tumors. A baseline Tc-sestamibi scan was obtained before the administration of tariquidar. A minimum of 48 hours later, on or about day 22 a single dose of tariquidar was administered, followed by a second Tc-sestamibi scan.</description>
        <time_frame>3 - 24 hours</time_frame>
        <population>Percent increase in sestamibi AUC in liver after tariquidar.</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients Who Received Docetaxel and Tariquidar</title>
            <description>Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Increase in Sestamibi Area Under Curve (AUC) in Liver After Tariquidar</title>
          <description>A significant change in the area under the curve(AUC) in liver tissue (normal tissue as a surrogate) is defined as P&lt;0.001. A secondary objective of this study was to establish whether tariquidar (150 mg) modulates Pgp in liver. Sestamibi is a Pgp substrate that may be a surrogate for measuring drug efflux from tumors. A baseline Tc-sestamibi scan was obtained before the administration of tariquidar. A minimum of 48 hours later, on or about day 22 a single dose of tariquidar was administered, followed by a second Tc-sestamibi scan.</description>
          <population>Percent increase in sestamibi AUC in liver after tariquidar.</population>
          <units>percent increase in sestamibi AUC</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.2" lower_limit="5.8" upper_limit="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Increase in Sestamibi Area Under Curve (AUC) in Tumor Tissue</title>
        <description>99mTc-sestamibi is a radionuclide imaging agent used to study cardiac function that has also been shown to be a substrate for P-glycoprotein- mediated drug efflux. Because of the high expression of Pgp in liver tissue, sestamibi uptake in liver tissue is often monitored as a marker of Pgp inhibition. A significant change in the area under the curve(AUC) in liver tissue (normal tissue as a surrogate) is defined as P&lt;0.001.</description>
        <time_frame>3-24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients Who Received Docetaxel and Tariquidar</title>
            <description>Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Increase in Sestamibi Area Under Curve (AUC) in Tumor Tissue</title>
          <description>99mTc-sestamibi is a radionuclide imaging agent used to study cardiac function that has also been shown to be a substrate for P-glycoprotein- mediated drug efflux. Because of the high expression of Pgp in liver tissue, sestamibi uptake in liver tissue is often monitored as a marker of Pgp inhibition. A significant change in the area under the curve(AUC) in liver tissue (normal tissue as a surrogate) is defined as P&lt;0.001.</description>
          <units>Percent</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="7.2" upper_limit="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years and 11 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Patients on Docetaxel on Days 1, 8 &amp; Tariquidar on Day 8, 22</title>
          <description>Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.</description>
        </group>
        <group group_id="E2">
          <title>Patients on Docetaxel on Days 1, 8 &amp; Tariquidar on Days 1, 22</title>
          <description>Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA10/CTCv2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIOVASCULAR (GENERAL):: Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR (GENERAL):: Thrombosis/embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROINTESTINAL:: Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE:: Rectal bleeding/hematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTITUTIONAL SYMPTOMS:: Fatigue (lethargy, malaise, asthenia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>CONSTITUTIONAL SYMPTOMS::</sub_title>
                <description>Fever (in the absence of neutropenia, where neutropenia is defined as AGC&lt;1.0 x 10e9/L)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>CONSTITUTIONAL SYMPTOMS:: Rigors, chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFECTION/FEBRILE NEUTROPENIA:: Febrile neutropenia (fever of unknown origin without clinically or m</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>HEPATIC:: Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>HEPATIC:: SGOT (AST) (serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>HEPATIC:: SGPT (ALT) (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULOSKELETAL:: Musculoskeletal-Other (Specify,musculoskeletal-lethargic)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL:: Muscle weakness (not due to neuropathy)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUROLOGY:: Dizziness/lightheadedness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Mood alteration-anxiety, agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY:: Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>PULMONARY:: Pulmonary-Other (Specify,clinical deterioration)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>PULMONARY:: Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA10/CTCv2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Hemoglobin</sub_title>
                <counts group_id="E1" events="130" subjects_affected="18" subjects_at_risk="23"/>
                <counts group_id="E2" events="72" subjects_affected="21" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="86" subjects_affected="18" subjects_at_risk="23"/>
                <counts group_id="E2" events="77" subjects_affected="21" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Lymphopenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="21" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="62" subjects_affected="19" subjects_at_risk="23"/>
                <counts group_id="E2" events="41" subjects_affected="16" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Platelets</sub_title>
                <counts group_id="E1" events="22" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E2" events="31" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Transfusion: pRBCs</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>COAGULATION:: Partial thromboplastin time (PTT)</sub_title>
                <counts group_id="E1" events="17" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>COAGULATION:: Prothrombin time (PT)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="13" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE:: CNS hemorrhage/bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIOVASCULAR (ARRHYTHMIA):: Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR (GENERAL):: Edema</sub_title>
                <counts group_id="E1" events="18" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR (GENERAL):: Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR (GENERAL):: Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR (GENERAL):: Phlebitis (superficial)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR (GENERAL):: Thrombosis/embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR (ARRHYTHMIA):: Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>AUDITORY/HEARING:: Middle ear/hearing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>PAIN:: Earache (otalgia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>OCULAR/VISUAL:: Conjunctivitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>OCULAR/VISUAL:: Dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>OCULAR/VISUAL:: Tearing (watery eyes)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>OCULAR/VISUAL:: Ocular/Visual-Other (Specify,___)</sub_title>
                <description>uveitis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>OCULAR/VISUAL:: Vision-blurred vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROINTESTINAL:: Anorexia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="23"/>
                <counts group_id="E2" events="21" subjects_affected="13" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Constipation</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Diarrhea patients without colostomy</sub_title>
                <counts group_id="E1" events="33" subjects_affected="17" subjects_at_risk="23"/>
                <counts group_id="E2" events="37" subjects_affected="17" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Dyspepsia/heartburn</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Dysphagia, esophagitis, odynophagia (painful swallowing)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Gastrointestinal-Other (Specify,_____)</sub_title>
                <description>gastrointestinal: tooth fracture</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Mouth dryness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Nausea</sub_title>
                <counts group_id="E1" events="34" subjects_affected="13" subjects_at_risk="23"/>
                <counts group_id="E2" events="19" subjects_affected="12" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Stomatitis/pharyngitis (oral/pharyngeal mucositis)</sub_title>
                <counts group_id="E1" events="18" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Taste disturbance (dysgeusia)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" events="17" subjects_affected="10" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Vomiting</sub_title>
                <counts group_id="E1" events="17" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Mucositis due to radiation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="19" subjects_affected="12" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE:: Rectal bleeding/hematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTITUTIONAL SYMPTOMS:: Fatigue (lethargy, malaise, asthenia)</sub_title>
                <counts group_id="E1" events="42" subjects_affected="18" subjects_at_risk="23"/>
                <counts group_id="E2" events="56" subjects_affected="21" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>CONSTITUTIONAL SYMPTOMS:: Fever (in the absence of neutropenia, where neutropenia is defined as AGC&lt;</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>CONSTITUTIONAL SYMPTOMS:: Rigors, chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>CONSTITUTIONAL SYMPTOMS:: Weight loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>PAIN:: Chest pain (non-cardiac and non-pleuritic)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGY/IMMUNOLOGY:: Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>ALLERGY/IMMUNOLOGY:: Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>ALLERGY/IMMUNOLOGY:: Allergy-Other (Specify,_____)</sub_title>
                <description>allergy:reaction to tariquidar</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFECTION/FEBRILE NEUTROPENIA:: Catheter-related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>INFECTION/FEBRILE NEUTROPENIA::</sub_title>
                <description>Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infection) (ANC &lt;1.0x10e9/L, fever &gt;=38.5 degrees C)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>INFECTION/FEBRILE NEUTROPENIA::</sub_title>
                <description>Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia (ANC &lt;1.0 x 10e9/L)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>INFECTION/FEBRILE NEUTROPENIA:: Infection without neutropenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>INFECTION/FEBRILE NEUTROPENIA:: Infection/Febrile Neutropenia-Other (Specify,____)</sub_title>
                <description>infection-thrush</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>HEPATIC:: Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>HEPATIC:: Bilirubin</sub_title>
                <counts group_id="E1" events="14" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>HEPATIC:: SGOT (AST) (serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>HEPATIC:: SGPT (ALT) (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: CPK (creatine phosphokinase)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Hemoglobin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="72" subjects_affected="20" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hyperuricemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC:: Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="16" subjects_at_risk="23"/>
                <counts group_id="E2" events="40" subjects_affected="12" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Bicarbonate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hypercalcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hyperglycemia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E2" events="23" subjects_affected="11" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hyperkalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hypermagnesemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hypernatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hypocalcemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E2" events="21" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hypomagnesemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hyponatremia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="14" subjects_at_risk="23"/>
                <counts group_id="E2" events="26" subjects_affected="15" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hypophosphatemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hypokalemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULOSKELETAL:: Muscle weakness (not due to neuropathy)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>PAIN:: Arthralgia (joint pain)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>PAIN:: Bone pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>PAIN:: Myalgia (muscle pain)</sub_title>
                <counts group_id="E1" events="22" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUROLOGY:: Ataxia (incoordination)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Confusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Dizziness/lightheadedness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Extrapyramidal/involuntary movement/restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Mood alteration-depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Neuropathy-sensory</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Seizure(s)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Syncope (fainting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>PAIN:: Neuropathic pain (e.g., jaw pain, neurologic pain, phantom limb pain, post-infectious neuralg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain-Other (Specify,___)</sub_title>
                <description>Back pain Hips + Legs pain-lumbar pain: back pain pain: sore throat pain: chest tube site pain: L flank lower pain: lower back pain pain: lower back</description>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>PAIN:: Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Mood alteration-anxiety, agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL/GENITOURINARY:: Creatinine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>RENAL/GENITOURINARY:: Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE:: Hematuria (in the absence of vaginal bleeding)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>RENAL/GENITOURINARY:: Dysuria (painful urination)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>RENAL/GENITOURINARY:: Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN:: Abdominal pain or cramping</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>PAIN:: Pelvic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>HEMORRHAGE:: Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>PULMONARY:: Cough</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>PULMONARY:: Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>PULMONARY:: Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>PULMONARY:: Pulmonary-Other (Specify,___)</sub_title>
                <description>pleural effusion (malignant)</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>PULMONARY:: Voice changes/stridor/larynx (e.g., hoarseness, loss of voice, laryngitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>PULMONARY:: Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Alopecia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Dermatology/Skin-Other (Specify,_____)</sub_title>
                <description>dermatology/skin: red peeling skin-face</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Dry skin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Erythema multiforme (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Flushing</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Nail changes</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Radiation dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Rash/desquamation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Bruising (in absence of grade 3 or 4 thrombocytopenia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Wound-non-infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susan E. Bates, M.D.</name_or_title>
      <organization>National Cancer Institute, National Institutes of Health</organization>
      <phone>301-402-1357</phone>
      <email>BatesS@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

